


PHARMACEUTICAL 2020

LANDEC CORP \CA\ Rank 59 of 362







PHARMACEUTICAL 2020



LANDEC CORP \CA\ Rank 59 of 362



The relative strengths and weaknesses of LANDEC CORP \CA\ are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LANDEC CORP \CA\ compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 554% points. The greatest weakness of LANDEC CORP \CA\ is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 464% points.

The company's Economic Capital Ratio, given in the ranking table, is 77%, being 380% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	133,041
Cost of Goods Sold	476,556
Intangible Assets	76,742
Liabilities, Current	137,091
Liabilities, Non-Current	87,193
Other Assets	109,308
Other Compr. Net Income	-1,084
Other Expenses	6,748
Other Liabilities	24,663
Other Net Income	1,684
Property and Equipment	200,000
Research and Development	11,466
Revenues	557,559
Selling, General and Administrative Expense	64,062

Output Variable	Value in 1000 USD
Assets	519,091
Liabilities	248,947
Expenses	558,832
Stockholders Equity	270,144
Net Income	411
Comprehensive Net Income	-131
Economic Capital Ratio	77%